Vision Restored: Science Corporation Secures Landmark Approval for PRIMA Bionic Eye

In a monumental leap for neurotechnology and ophthalmology, Science Corporation—the brain-computer interface (BCI) startup founded by former Neuralink president Max Hodak—has achieved a critical regulatory milestone. The company recently secured the CE Mark, granting it authorization to market its PRIMA vision-restoration system across Europe. This approval signals a transition from experimental clinical research to commercial availability, offering a lifeline to millions suffering from age-related macular degeneration (AMD).

The PRIMA system represents a sophisticated fusion of optical engineering and neuro-prosthetics. By effectively bypassing damaged photoreceptors in the eye, the device restores functional sight, allowing patients to perform complex tasks that were previously impossible. As Science Corporation prepares for its first commercial procedures in Germany, the medical community is watching closely, noting that this technology may represent the first viable, scalable BCI business model.

The Science of Sight: How PRIMA Works

Age-related macular degeneration remains a leading cause of blindness in the developed world. It specifically targets the macula—the center of the retina responsible for sharp, central vision—by destroying the light-sensitive cells necessary for reading, recognizing faces, and navigating intricate environments.

The PRIMA device addresses this pathology through a two-part, outpatient procedure. First, a tiny, wireless photovoltaic chip is implanted behind the retina. Once the surgical site heals, the patient wears a pair of specially designed, camera-equipped glasses. These glasses capture the visual field in real-time and project the data onto the chip via infrared pulses. The chip converts these signals into electrical impulses that stimulate the remaining healthy neurons in the retina, which then transmit the information to the brain via the optic nerve.

The result is not "perfect" natural vision, but rather a functional, high-contrast visual feed that allows for significant autonomy. Max Hodak, CEO of Science Corporation, emphasizes that the impact on patient quality of life is profound. "One of our patients in France finished a 300-page novel a little while ago, and sent us the book," Hodak shared. "We have a sketch on the wall that one of our patients drew of the Sydney Opera House. There are videos of patients playing crossword puzzles and filling in Sudoku."

Chronology of a Breakthrough

The road to the PRIMA system’s approval has been a multi-year journey involving iterative design and strategic acquisitions:

• Pre-2021: The foundational technology behind PRIMA was developed by the French firm Pixium Vision. The company spent years refining the hardware and conducting initial clinical trials in Europe to prove the safety and efficacy of the retinal implant.
• 2021: Max Hodak departs Neuralink to found Science Corporation. His stated goal is to build a company that bridges the gap between ambitious, long-term BCI research and the practical realities of a sustainable, revenue-generating business.
• 2023–2024: Recognizing that the PRIMA technology was the "right path forward" for immediate clinical impact, Science Corporation initiates the acquisition of Pixium Vision.
• 2024: Following the acquisition, Science Corporation leverages its internal engineering platform to finalize the regulatory documentation and product refinements necessary to satisfy European medical device standards.
• Mid-2025: Science Corporation receives the CE Mark, authorizing commercial sales in the European Union. Simultaneously, the company receives a "Breakthrough Device" designation from the U.S. Food and Drug Administration (FDA), fast-tracking the path toward treating rare forms of blindness in the American market.

Supporting Data and Commercial Strategy

The financial and operational architecture of Science Corporation is unique in the BCI sector. While many competitors focus exclusively on high-risk, high-reward brain implants, Hodak has adopted a "stair-step" strategy. By acquiring a near-market-ready product, the company has bypassed the "valley of death"—the period where startups often run out of cash before achieving regulatory approval.

Market Economics

Each PRIMA unit is expected to retail for hundreds of thousands of dollars. Currently, Science Corporation is engaged in high-level negotiations with European healthcare providers and insurance entities to establish reimbursement models. The first commercial procedures are slated to begin in Germany as early as September.

The Sustainability Mandate

Hodak has been vocal about the "winter" that often plagues emerging tech sectors when funding dries up before products reach the market. "The thing that the space needs is a company making $100 million a year of revenue," Hodak noted. "There’s this risk that the whole thing enters a winter, and so we think it’s important to build a sustainable business as we develop these longer-term technologies."

By generating revenue through the PRIMA device, Science Corporation is effectively self-funding its more speculative research. This includes the development of the "bio-hybrid" brain sensor, a more ambitious BCI project currently being developed in collaboration with Dr. Murat Günel, chair of the Department of Neurosurgery at Yale Medical School.

Official Responses and Strategic Implications

The industry reaction to Science Corporation’s success has been largely optimistic, though guarded by the realities of medical adoption. Regulatory bodies have praised the rigorous clinical trial data provided by the company, noting that the PRIMA system fills a significant gap in treatment options for the elderly.

Bridging to Future BCIs

The implications for the broader BCI industry are significant. If Science Corporation can demonstrate that a neuro-prosthetic company can be profitable, it will likely trigger an influx of institutional investment into the sector. Investors have historically struggled to build "spreadsheets" around the long-term, ill-defined timelines of experimental BCI research. By offering a concrete, revenue-generating product in the vision space, Hodak has provided a blueprint for other startups to follow.

Technical Roadmaps

Science Corporation is not resting on its current success. The company’s engineering roadmap includes:

1. Hardware Iteration: Developing a next-generation chip with higher resolution and faster refresh rates.
2. Form Factor Optimization: The current system requires a battery pack and specialized glasses. The long-term goal is to migrate the technology toward a sleek, AR-style wearable that blends into everyday life.
3. Bio-Hybrid Integration: Utilizing the revenue from PRIMA to finance the deep-tissue brain sensors that could one day restore motor control to paralyzed patients or address other neurological conditions.

Looking Ahead: The Intersection of Biology and Silicon

The success of the PRIMA system serves as a proof of concept for the "bio-hybrid" philosophy. By integrating silicon chips directly with human physiology, Science Corporation is demonstrating that the future of medicine lies not in drugs alone, but in the precise, electrical orchestration of the body’s internal systems.

While the primary focus remains on restoring vision, the broader mission of the company is to prove that deep-tech hardware can be commercially viable. As Hodak noted, "Bringing PRIMA to market is the most important thing for the company, because we don’t get to do the bio-hybrid stuff long term if you don’t have a great vision business."

For patients suffering from age-related macular degeneration, the wait for a solution is effectively over. For the rest of the world, Science Corporation’s journey is just beginning—providing a rare glimpse into a future where the limitations of biology are no longer permanent.

Disclaimer: This report is for informational purposes and does not constitute financial or medical advice. Science Corporation’s progress in the U.S. market remains subject to ongoing FDA review processes.